The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1566
ISSUE 1566
February 25, 2019
Fostamatinib (Tavalisse) for ITP
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
February 25, 2019 (Issue: 1566)
The FDA has approved fostamatinib disodium
hexahydrate (Tavalisse – Rigel), the first spleen
tyrosine kinase (SYK) inhibitor, for oral treatment of
thrombocytopenia in adults with chronic immune
thrombocytopenia (ITP) who have had an insufficient
response to a previous treatment.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Fostamatinib (Tavalisse) for ITP
Article code: 1566c
Electronic, downloadable article - $45
Article code: 1566c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
